妇产科

订阅

MedSci主页 / 所有栏目 / 妇产科

Clinica Chimica Acta：华北地区不同人群CD36抗原缺乏、血小板同种异体抗体分布及血小板同种异体抗体对妊娠影响？

2019-12-02 gladiator MedSci原创

抗体妊娠
关注

血小板抗体可导致血小板输血难<span lang="EN-US" style="font-size:12.0pt;mso-bidi-font-size:14.0pt;font-family:&quot;Calibri&quot;,&quot;sans-serif&quot;; mso-fareast-font-family:宋体;mso-bidi-font-family:&quot;Times

血小板抗体可导致血小板输血难(PTR)、胎儿/新生儿同种免疫性血小板减少(FNAIT)等临床疾病。本研究旨在了解华北地区不同人群CD36表达、血小板同种抗体分布及血小板同种抗体对妊娠的影响。

已进入以通过采集血液病患者、孕妇、献血者等612例受试者全血标本，检测CD36表达，进行血小板抗体筛选及特异性鉴定。为了调查FNAIT的发生，对1552例产科住院孕妇进行回顾性分析。

研究结果显示，CD36缺乏症表达率为2.12%(13/612)，所有病例均为II型缺乏症，而未检出I型缺乏症，总体而言，该率低于华南地区(3.43%)、日本(4.87%)和黑人(4.18%)，但高于白人(0.09%)。积极的血小板抗体筛选血液病人组(6.86%,14/204)和孕妇组(6.31%,13/206)高于献血者组(0.49%,1/202),P < . 01。在1552名孕妇中，没有儿童患有FNAIT。

研究结果表明，北方地区CD36缺乏的频率较低，均为II型，未检出CD36抗体。推测该人群因CD36缺乏而导致免疫相关血小板减少的风险极低。血液学和多次流产的患者应早期监测血小板抗体。

原始出处：

Chunya Ma，Jinhui Wang，A single-center investigational study of CD36 antigen deficiency and platelet Chunya Maalloantibody distribution in different populations in Northern China as well as platelet alloantibodies effect on pregnancy

本文系梅斯医学（MedSci）原创编译整理，转载需授权！


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1687989, encodeId=66a3168e98945, content=<a href='/topic/show?id=b3e73898423' target=_blank style='color:#2F92EE;'>#同种异体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38984, encryptionId=b3e73898423, topicName=同种异体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23b928427427, createdName=12498768m22(暂无昵称), createdTime=Fri Dec 13 05:01:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849811, encodeId=164b184981196, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Sep 27 10:01:00 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587568, encodeId=7512158e5686b, content=<a href='/topic/show?id=b3e8431584' target=_blank style='color:#2F92EE;'>#CD36#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4315, encryptionId=b3e8431584, topicName=CD36)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251317505885, createdName=crystal0568, createdTime=Wed Dec 04 13:01:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623359, encodeId=6d77162335931, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Wed Dec 04 13:01:00 CST 2019, time=2019-12-04, status=1, ipAttribution=)]
    2019-12-13 12498768m22(暂无昵称)

    #同种异体#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1687989, encodeId=66a3168e98945, content=<a href='/topic/show?id=b3e73898423' target=_blank style='color:#2F92EE;'>#同种异体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38984, encryptionId=b3e73898423, topicName=同种异体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23b928427427, createdName=12498768m22(暂无昵称), createdTime=Fri Dec 13 05:01:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849811, encodeId=164b184981196, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Sep 27 10:01:00 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587568, encodeId=7512158e5686b, content=<a href='/topic/show?id=b3e8431584' target=_blank style='color:#2F92EE;'>#CD36#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4315, encryptionId=b3e8431584, topicName=CD36)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251317505885, createdName=crystal0568, createdTime=Wed Dec 04 13:01:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623359, encodeId=6d77162335931, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Wed Dec 04 13:01:00 CST 2019, time=2019-12-04, status=1, ipAttribution=)]
    2020-09-27 windight

    #CTA#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1687989, encodeId=66a3168e98945, content=<a href='/topic/show?id=b3e73898423' target=_blank style='color:#2F92EE;'>#同种异体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38984, encryptionId=b3e73898423, topicName=同种异体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23b928427427, createdName=12498768m22(暂无昵称), createdTime=Fri Dec 13 05:01:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849811, encodeId=164b184981196, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Sep 27 10:01:00 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587568, encodeId=7512158e5686b, content=<a href='/topic/show?id=b3e8431584' target=_blank style='color:#2F92EE;'>#CD36#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4315, encryptionId=b3e8431584, topicName=CD36)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251317505885, createdName=crystal0568, createdTime=Wed Dec 04 13:01:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623359, encodeId=6d77162335931, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Wed Dec 04 13:01:00 CST 2019, time=2019-12-04, status=1, ipAttribution=)]
    2019-12-04 crystal0568

    #CD36#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1687989, encodeId=66a3168e98945, content=<a href='/topic/show?id=b3e73898423' target=_blank style='color:#2F92EE;'>#同种异体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38984, encryptionId=b3e73898423, topicName=同种异体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23b928427427, createdName=12498768m22(暂无昵称), createdTime=Fri Dec 13 05:01:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849811, encodeId=164b184981196, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Sep 27 10:01:00 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587568, encodeId=7512158e5686b, content=<a href='/topic/show?id=b3e8431584' target=_blank style='color:#2F92EE;'>#CD36#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4315, encryptionId=b3e8431584, topicName=CD36)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251317505885, createdName=crystal0568, createdTime=Wed Dec 04 13:01:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623359, encodeId=6d77162335931, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Wed Dec 04 13:01:00 CST 2019, time=2019-12-04, status=1, ipAttribution=)]
    2019-12-04 xiaoyeshuang

    #抗原#

    0

相关资讯

Microbiome：金黄色葡萄球菌产物引发自身性免疫

南卡罗莱纳的研究人员在《Microbiome》报告，接受抗逆转录病毒治疗的HIV阳性患者的自身抗体生产与血液中葡萄球菌产物水平有关。

白血病治疗耐药怎么办？新疗法“从抗体开始 根除癌细胞

在影视剧中，白血病一度是“绝症”的代名词。其中急性白血病进展很快，若不治疗，生存期很短。急性白血病通常又可分为急性淋巴细胞白血病(ALL)和急性髓细胞白血病(AML)。急性淋巴细胞白血病(ALL)是一种起源于淋巴细胞的B系或T系细胞在骨髓内异常增生的恶性血液肿瘤，约占成人白血病的1/5，也是最常见的儿童癌症之一。

NEJM：基于抗体的替卡格雷逆转剂效果分析

由此可见，在健康志愿者中，通过多次检查测量，替卡格雷的特异性逆转剂PB2452可使替卡格雷的抗血小板作用立即和持续逆转。

Sci Transl Med：自身免疫性疾病怎么治？以炎治炎

近日，加拿大基南生物医学科学研究中心（KRCBS）的科学家们在Science子刊中发表了一篇最新研究。他们通过研究发现，对于自身免疫性疾病的治疗，用炎症治疗炎症或许是未来潜在的药物靶点。

生物药外包服务发展现状分析

得益于数量庞大的生物技术人才，生物药研发创业企业蓬勃发展，中国药品上市许可人制度(MAH)试点的实施，我国生物药外包服务市场迅速发展，很多园区通过重点扶持生物药外包服务公司建设当地的生物医药研发生态圈。

常见风湿免疫指标，怎么解读？都这这里 ！

初步解读常见风湿免疫指标。